TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial.

TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. Gastroenterology. 2021 11; 161(5):1475-1486.

View in: PubMed

subject areas

Adult
Biomarkers
Enzyme Inhibitors
Fatty Acid Synthase, Type I
Female
Humans
Lipids
Lipogenesis
Liver
Liver Cirrhosis
Male
Middle Aged
Nitriles
Non-alcoholic Fatty Liver Disease
Piperidines
Single-Blind Method
Time Factors
Treatment Outcome
Triazoles
United States

authors with profiles

Mary Rinella